Hepatitis C

• 

  Subject Areas on Research

  • A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. 
  • A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. 
  • A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design. 
  • A flexible statistical model for alignment of label-free proteomics data--incorporating ion mobility and product ion information. 
  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 
  • A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. 
  • Acquired subretinal flecks secondary to hypovitaminosis A in a patient with hepatitis C. 
  • Activation and evasion of antiviral innate immunity by hepatitis C virus. 
  • Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. 
  • Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Antisense inhibitors, ribozymes, and siRNAs. 
  • Ascites in hepatitis C liver transplant recipients frequently occurs in the absence of advanced fibrosis. 
  • Association between hepatitis B virus and pancreatic cancer. 
  • Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C. 
  • Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. 
  • Chronic kidney disease in HIV infection: an urban epidemic. 
  • Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis. 
  • Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. 
  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. 
  • Combined factor IX and XI deficiency discovered at liver biopsy. 
  • Community-based HCV screening: knowledge and attitudes in a high risk urban population. 
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. 
  • Compliance with referral for hepatitis C evaluation among veterans. 
  • Concerted use of immunologic and ultrastructural analyses in diagnostic medicine: immunoelectron microscopy and correlative microscopy. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. 
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. 
  • Convergent evolution of escape from hepaciviral antagonism in primates. 
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. 
  • Coordination, Cost, and Changing Epidemiology-Considerations in the Hepatitis C Care Cascade. 
  • Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination. 
  • Current Management of Hepatitis C Virus Infection. 
  • DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. 
  • Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. 
  • Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Determining the Incidence of Hepatitis C Virus Infection in Populations: An Important Tool for Epidemic Control. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. 
  • Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Does this patient with liver disease have cirrhosis? 
  • Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. 
  • Don't share razors or toothbrushes. 
  • Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. 
  • Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation. 
  • Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. 
  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. 
  • Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level. 
  • Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. 
  • Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. 
  • Elevated serum CA-125 levels: hepatitis or ascites? 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. 
  • Emerging roles for lipid droplets in immunity and host-pathogen interactions. 
  • Evaluation for Fibrosis After Cure of Hepatitis C-Reply. 
  • Expanding the use of hepatitis C-viremic kidney donors. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. 
  • Future therapy of hepatitis C. 
  • Future trends in managing hepatitis C. 
  • GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality. 
  • Gender differences in hepatitis C infection and risks among persons with severe mental illness. 
  • Genotype 3 Infection: The Last Stand of Hepatitis C Virus. 
  • HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an Epidemic. 
  • HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 
  • HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. 
  • Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. 
  • Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. 
  • Hepatitis B and C viruses in infants and young children. 
  • Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. 
  • Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy. 
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
  • Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A. 
  • Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 
  • Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. 
  • Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. 
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 
  • Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 
  • Hepatitis C in Pregnancy: Review of Current Knowledge and Updated Recommendations for Management. 
  • Hepatitis C in pregnancy. 
  • Hepatitis C infection in children with hemophilia A and B. 
  • Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. 
  • Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. 
  • Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. 
  • Hepatitis C. 
  • Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. 
  • IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. 
  • IL28B in the era of direct-acting antivirals for hepatitis C. 
  • Identification and comparative analysis of hepatitis C virus-host cell protein interactions. 
  • Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. 
  • Impact of donor and recipient hepatitis C status in lung transplantation. 
  • Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. 
  • Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. 
  • Improving Access to Hepatitis C Treatment Using Clinical Pharmacist Services in an Uninsured, At-Risk Population at a Community Health Center. 
  • Improving HCV Risk Assessment and Testing in a Federally Qualified Health Center Setting in Baltimore, Maryland. 
  • Improving Hepatitis C Identification: Technology Alone Is Not the Answer. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • In the clinic. Hepatitis C. 
  • Index of suspicion. 
  • Induction immunosuppression in liver transplantation: a review. 
  • Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. 
  • Infectious complications in extended criteria heart transplantation. 
  • Innovation, diffusion and safety of a medical technology: a review of the literature on injection practices. 
  • Innovations in Heart Transplantation: A Review. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Insights into antiviral innate immunity revealed by studying hepatitis C virus. 
  • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 
  • Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. 
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC. 
  • Is the HCV pipeline heading in the right direction? 
  • Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. 
  • Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. 
  • Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. 
  • Maximizing utilization of the donor pool by appropriate classification of hepatitis C antibody-positive donors. 
  • Measuring Hepatitis C Virus Envelopment by Using a Proteinase K Protection Assay. 
  • Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. 
  • Membranoproliferative glomerulonephritis type I, mixed cryoglobulinemia and lymphoma in the absence of hepatitis C infection. 
  • Meningococcemia in a patient coinfected with hepatitis C virus and HIV. 
  • Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. 
  • Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. 
  • Mixed model analysis of censored longitudinal data with flexible random-effects density. 
  • Motivations for donating and attitudes toward screening policies in US blood donors with viral infection. 
  • Multiinstitutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients With Hepatitis C. 
  • Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. 
  • NASH and cryptogenic cirrhosis: a histological analysis. 
  • Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. 
  • New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. 
  • Non-A, non-B hepatitis and chronic dialysis--another dilemma. 
  • Non-Hodgkin's lymphomas, version 1.2013. 
  • Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Overcoming barriers to care for hepatitis C. 
  • Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. 
  • Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. 
  • Predictors of proteinuria and renal failure among women with HIV infection. 
  • Pregnancy outcomes associated with viral hepatitis. 
  • Premature Rupture of Membranes with Concurrent Viral Infection. 
  • Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. 
  • Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. 
  • Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. 
  • Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. 
  • Providing primary care for long-term survivors of childhood acute lymphoblastic leukemia. 
  • Pure red cell aplasia following pegylated interferon alpha treatment. 
  • Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong. 
  • Recurrent demyelinating myelitis associated with hepatitis C viral infection. 
  • Regular sources of medical care among persons with severe mental illness at risk of hepatitis C infection. 
  • Regulation of hepatic innate immunity by hepatitis C virus. 
  • Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". 
  • Results of a pilot test of a brief computer-assisted tailored HIV prevention intervention for use with a range of demographic and risk groups. 
  • Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. 
  • Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. 
  • Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. 
  • Risks of a range of alcohol intake on hepatitis C-related fibrosis. 
  • Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. 
  • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. 
  • Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin. 
  • Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. 
  • Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. 
  • Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. 
  • Shifting Away From Fee-For-Service: Alternative Approaches to Payment in Gastroenterology. 
  • Short and Long-Term Postoperative Complications Following Total Joint Arthroplasty in Patients With Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C. 
  • Silent damage? Occult HCV replication and histological disease may occur following apparent HCV clearance. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Staphylococcus aureus pericardial abscess in a patient with liver cirrhosis: case report. 
  • Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. 
  • Streptococcus equi primary bacteremia in a hepatitis-C cirrhotic patient. 
  • Substance abuse and the transmission of hepatitis C among persons with severe mental illness. 
  • Successes and Challenges on the Road to Cure Hepatitis C. 
  • Surveillance for hepatocellular carcinoma. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • Syringe exchanges: a public health response to problem drug use. 
  • Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020. 
  • The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year. 
  • The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. 
  • The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. 
  • The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 
  • The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 
  • The five-site health and risk study of blood-borne infections among persons with severe mental illness. 
  • The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The hepatitis C crisis in the African American Community: findings and recommendations. 
  • The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. 
  • The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. 
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. 
  • The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services. 
  • The natural history of hepatitis C viral infection. 
  • Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. 
  • Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of hepatitis C in special populations. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Ultrasound guided biopsy: what's new? 
  • Undetectable Hepatitis C Viral Load Is Associated With Improved Outcomes Following Total Joint Arthroplasty. 
  • Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. 
  • Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. 
• 

  Keywords of People

  • Horner, Stacy M., Associate Professor of Molecular Genetics and Microbiology, Duke Science & Society
  • Knechtle, Stuart Johnston, William R. Kenan, Jr. Distinguished Professor, Medicine, Nephrology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Andrew Joseph, Professor of Medicine, Duke Innovation & Entrepreneurship
  • Tsalik, Ephraim, Adjunct Associate Professor in the Department of Medicine, Medicine, Infectious Diseases
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine